Navigation Links
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
Date:5/31/2013

HILDEN, Germany and MARSEILLE, France, May 31, 2013 /PRNewswire/ --

 

  • FGFR-TACC fusion genes, the target of potential targeted therapies for glioblastoma and other cancers, rights acquired from Columbia University
  • Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced two agreements adding promising new biomarkers involving glioblastoma, lymphoma and other cancers to QIAGEN's expanding portfolio of potential companion diagnostics that is being developed to help doctors use a patient's genomic information to guide treatment decisions.

In the glioblastoma project, QIAGEN has entered into an exclusive worldwide licensing option on FGFR-TACC fusion genes with Columbia University in New York. QIAGEN intends to develop this biomarker into a diagnostic test for routine use in diagnostic workups, which may enable doctors to identify glioblastoma patients who could benefit from targeted treatments now under development. Glioblastoma is the most common and aggressive form of primary brain tumor, a serious unmet medical need because the disease is generally fatal despite aggressive therapy. Fusions between members of the FGFR and TACC gene families also have been identified recently as present in several other malignancies, including bladder cancers.

QIAGEN has also entered into an exclusive license option with the BC Cancer Agency, based in Vancouver, British Columbia, Canada, for the EZH2 Y641 mutation biomarker that could serve as a companion diagnostic test for routine selection of patients who could benefit from E
'/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
2. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
3. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
4. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
5. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
6. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
7. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
8. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
9. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
10. S1 Biopharma Expands Focus to Include Male Sexual Health
11. PRA Expands Operations in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
(Date:10/17/2014)... , Oct. 17, 2014 With the ... Affairs function has come across several challenges in ... and managing globalization.  The ... is dedicated to providing benchmarking and best practices ... Consortium is a service composed of three stages: ...
(Date:10/17/2014)... Texas , Oct. 17, 2014  Hanger, Inc. ... plans to report its results of operations for the ... 2014 after the market closes.  A conference call to ... a.m., ET, on Friday, November 7, 2014. Those wishing ... available until Friday, November 14, 2014 by dialing 1-855-859-2056 ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Calif., Dec. 9, 2010 Ambry Genetics, a global ... sciences industries, announced today that it has officially launched ... Genetics has been an early adapter of Illumina sequencing ... Certified Service Provider. (Logo:   http://photos.prnewswire.com/prnh/20090428/LA06744LOGO ...
... 9, 2010 A new study shows that ... hormonal therapy tamoxifen in patients with hormone-receptor positive/human ... cancer who have been previously treated with an ... tamoxifen alone. These results were presented today at ...
Cached Medicine Technology:Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services 2Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 2Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 3Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 4Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 5Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 6Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 7Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 8Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 9Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 10Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients 11
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3
... home-based treatment for hand eczema is just as effective ... to // a new study. Eczema is an inflammatory ... scaling. ,Researchers examined 158 patients with moderate to ... About half the patients followed a home-based program taking ...
... therapy of acupuncture can help those suffering from arthritis ... ,A current multi-location trial included 570 patients ages ... were placed in three groups. One hundred and ninety ... followed a self-help course to manager their condition. The ...
... worldwide. A model based on the findings of a clinical ... severity of acute appendicitis, // according to a new study. ... 89 who underwent an appendectomy within three days of an ... the actual severity of acute appendicitis. The study showed CT, ...
... million people worldwide and is caused by abnormal surges in ... seizures. More than half of those with epilepsy can live ... is under way to determine just how effective surgery is ... epilepsy, the most common form of the disorder. Typically, about ...
... suggests getting active can help elderly patients who have trouble ... between the ages of 67 and 86 in a 90-minute ... exercise followed by 30 minutes of seated social activity and ... in the morning or in the evening, with all participants ...
... pain relief and improves function for people with ... effective complement to Normal care. This study was ... Alternative Medicine (NCCAM) and the National Institute of ... components of the National Institutes of Health.// The ...
Cached Medicine News:Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 2Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 3
... An integrated approach to quality patient care., ... an innovative approach to anesthesia delivery. As ... combines enhanced ventilation features, electronically controlled gas ... and information management to create a truly ...
A non-adhering hydrogel sheet dressing for use on all partial and full thickness wounds (excluding 3rd degree burns.) Hydrogel sheet contains 96% water and 4% insoluble cross-linked polyethylene oxid...
... External Vacuum Therapy System restores sexual function ... Non-invasive and low cost vacuum therapy, coupled ... outcome", makes it the ideal therapy for ... System causes penile rigidity that can be ...
... D.O.R.C. Harmony Special Peristaltic phacoemulsification system features ... including individual programmability and remote control for ... a front panel with color coded function ... for ease of use and viewing. Under ...
Medicine Products: